Below for your information is a listing of the 2018 conferences and workshops. Mark your calendar for future IABS conferences, meetings and workshops and watch for future announcements regarding attendance and registration! If you are interested in a conference that was already held, check the IABS website ( for summary information from the event.

Narcolepsy and Pandemic Influenza Vaccination - an IABS-EU meeting

March 26-27, 2018 - In partnership with Federal Agency for Medicines and Health Products (FAMHP), Belgium

Objectives of the meeting

Influenza Pandemics occur when an influenza strain circulates that humans have been exposed to before. This may lead to widespread circulation and a high case fatality rate.

In 2009 pandemic, several H1N1 vaccines were developed against the new H1N1 virus and were extensively used. In Finland and Sweden an increase in narcolepsy was noted after the mass vaccination with one of these vaccines. Disparate results were seen in other countries with other vaccines. In addition, an increase of narcolepsy has been reported in countries in Asia following wild type influenza infection.

The goal of this meeting is to be prepared for the next pandemic:

  • What are the latest data on the risk of narcolepsy following exposure to 2009 pandemic vaccines?
  • What scientific data are available and what data are lacking to explain the phenomena that was seen in 2009-10?
  • What additional work is needed to prepare for potential use of adjuvanted vaccines for a future pandemic ?

Scientific committee

Steve Black
Co-chair; Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio
Liz Miller
Co-chair; Immunisation Hepatitis and Blood Safety Department, Public Health England, UK z Pieter Neels
IABS, Chair IABS Human Vaccine Committee
Daniel Brasseur
University Libre Bruxelles, Belgium
Christopher Jankosky
FDA Center for Biologics Evaluation and Research (CBER), Silver Spring, Maryland
Kari Johansen
European Centre for Disease Prevention and Control, Solna, Sweden
Brigitte Keller-Stanislavski
Paul-Ehrlich-Institut, Langen, Germany
Emmanuel Mignot
Stanford Center for Sleep Sciences and Medicine, Stanford University, California
Hanna Nohynek
National Institute for Health and Welfare, Helsinki, Finland
Tom Shimabukuro
Immunization Safety Office, Center for Disease Control and Prevention (CDC), Atlanta, Georgia
Lawrence Steinman
Beckman Center for Molecular Medicine, Stanford University, California

4th Cell Therapy Conference: Manufacturing and Testing of Pluripotent Stem Cells

June 5-6, 2018, Los Angeles Airport Marriott Hotel, USA

Objectives of the meeting

The 2018 Cell Therapy conference will identify key unresolved issues that need to be addressed for the manufacture and testing of pluripotent stem cell-based therapies and provide scientific consensus on selected aspects to inform the drafting of future national and international guidance. The meeting will bring together representatives from industry, academia, health services and regulatory bodies.

The overall goal of the conference is to provide the target audience with an appreciation of the importance of a well-controlled manufacturing process for cell therapies that are in development, and to hi-lite specific areas that should be considered during early product development in order to avoid issues in later stages. The target audience includes those individuals and organizations actively pursuing research and development of cell therapies with the intent of achieving pluripotent stem cell therapy products that meets regulatory requirements for approval, thus becoming generally available to treat patients with unmet medical needs.

We will build on previous meetings that generally addressed broader themes of cell therapy studies and manufacturing issues. In addition to reviewing information on the state-of-the-art and recently generated data, this conference ill drill down to key practical issues facing cell therapy developers and regulators to expedite the safe and efficient introduction of new treatments for important diseases where unmet medical needs exist.

More specifically, the conference is expected to provide a basis for new and/or additional guidance on regulatory expectations for developing acceptable pluripotent cell therapy products including testing requirements during manufacture. Concrete conclusions and recommendations will be important outcomes, which are expected to stimulate the field to move forward in a transparent and coordinated manner.

Scientific committee

Abla Creasey
California Institute of Regenerative Medicine (CIRM)
Stephen Lin
California Institute of Regenerative Medicine (CIRM)
Anthony Lubiniecki
International Alliance for Biological Standardization (IABS)
Glyn Stacey
John Petricciani
International Alliance for Biological Standardization (IABS)
Ivana Knezevic
World Health Organization (WHO)
Yoji Sato
National Institute of Health Sciences
Robert Deans
Blue Rock Therapeutics
Kathy Francissen
Thorsten Gorba
Elwyn Griffiths
International Alliance for Biological Standardization (IABS)
Karen Hoogendoorn
Leiden University Medical Center
Krish Roy
Bill & Melinda Gates Foundation
Jean-Hugues Trouvin
Université Paris Descartes
Kathy Zoon